The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma

Zheng Zhao, Ming-Mei Yin, Weifeng Zhao, Chao‐Jie WangMedicine 2023 · DOI

TL;DR

This retrospective study investigated the combination of sintilimab (an immunotherapy) with nanoparticle albumin-bound paclitaxel (Nab-PTX) and platinum chemotherapy as a first-line treatment for metastatic esophageal squamous cell carcinoma (ESCC). The combination showed promising efficacy with a high objective response rate and encouraging survival outcomes, while maintaining a manageable safety profile.

What Problem Does This Paper Address?

Esophageal squamous cell carcinoma (ESCC) is a significant global health challenge, and for patients with metastatic or recurrent disease, current first-line treatments, primarily platinum-based chemotherapy, offer limited survival benefits and can be associated with resistance and toxicity. While immunotherapy, particularly PD-1 inhibitors, has emerged as a promising treatment option, its combination with specific chemotherapy regimens like Nab-PTX and platinum as a first-line therapy for metastatic ESCC had not been extensively studied. This paper aims to fill that gap by evaluating the efficacy and safety of this novel combination.

Methods

This was a retrospective study involving 22 patients diagnosed with metastatic ESCC who received sintilimab in combination with Nab-PTX and either cisplatin or nedaplatin for up to 4-6 cycles. Following initial treatment, patients without progressive disease continued with sintilimab maintenance therapy. The primary endpoint was the objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Tumor response was assessed using RECIST criteria, and toxicities were graded according to CTCAE v5.0. Exploratory biomarker analysis was conducted to identify potential predictors of survival.

Datasets

The study utilized data retrospectively collected from 22 patients with metastatic ESCC treated at Henan Provincial People's Hospital between October 2019 and September 2022. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • Synergistic Potential: The combination of sintilimab with Nab-PTX and platinum appears to offer a synergistic effect, leading to improved anti-tumor activity compared to historical chemotherapy-only data.
  • Nab-PTX Advantage: Nab-PTX, as a novel solvent-free formulation, may distribute paclitaxel more efficiently to tumors and potentially reduce certain side effects or requirements (like dexamethasone pretreatment) compared to traditional paclitaxel.
  • LDH as a Prognostic Marker: Lactic dehydrogenase (LDH) emerged as a potential prognostic biomarker, with higher LDH levels correlating with poorer overall survival. This is an accessible and cost-effective marker that could aid in patient selection.
  • Manageable Safety Profile: Despite the combination of immunotherapy and chemotherapy, the treatment-related adverse events were predominantly grade 1 or 2, and importantly, no treatment-related deaths were observed.

Key Results

  • High Response Rates: The study achieved a high objective response rate (ORR) of 72.7% (16/22 patients), with 1 complete response (CR) and 15 partial responses (PR). The disease control rate (DCR) was also impressive at 90.9% (20/22).
  • Encouraging Survival: The median progression-free survival (PFS) was 8.9 months, and the median overall survival (OS) was 19.0 months.
  • Time to Response: Patients responded relatively quickly, with a median time to response of 1.9 months.
  • Adverse Events: Treatment-related adverse events (AEs) occurred in 95.5% of patients, but most were low-grade (1 or 2). Hematological toxicities (leukopenia, neutropenia, thrombocytopenia) and nausea/vomiting were common. Grade 3 or 4 AEs occurred in 45.5% of patients.
  • LDH and Survival: Patients with high LDH levels had a significantly shorter median OS (13.0 months) compared to those with low LDH levels, whose median OS was not reached (P = .004).

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: The study's retrospective nature and single-center design may introduce bias.
  • Small Sample Size: The small sample size (n=22) limits the statistical power and generalizability of the findings.
  • Univariate Analysis for LDH: The prognostic significance of LDH was only observed in univariate Cox regression, suggesting the need for further validation in larger cohorts.
  • Mechanism of Synergy: The precise underlying mechanisms for the synergistic effect between Nab-PTX and PD-1 inhibitors require further elucidation.

Future work should focus on validating these findings in larger, prospective, multi-center phase III trials to confirm the efficacy and safety of this combination regimen for metastatic ESCC. Further research into predictive biomarkers, including LDH, is also warranted.

Summary updated

Abstract

Immunotherapy is a new treatment option for patients with esophageal squamous cell carcinoma (ESCC). However, no study has investigated the efficacy and safety of sintilimab combined with nanoparticle albumin-bound paclitaxel (Nab-PTX) and platinum as first-line treatment for metastatic ESCC. In this retrospective study, eligible patients with metastatic ESCC were administered sintilimab plus Nab-PTX, cisplatin, or nedaplatin for up to 4 to 6 cycles. Subsequently, patients without progressive disease (PD) continued to receive sintilimab every 3 weeks as maintenance treatment until unacceptable toxicity, PD, withdrawal of consent, or for up to 2 years. The primary endpoint was the objective response rate (ORR) and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. A total of 22 patients diagnosed with metastatic ESCC were enrolled, 1 patient reached a complete response (CR), 15 patients achieved a partial response (PR), 4 patients had stable disease, and 2 had PD. The ORR was 72.7% (16/22) and the DCR was 90.9% (20/22). The time to response was 1.9 months (95% confidence interval [CI]:1.7-2.2 months). The median PFS was 8.9 months (95% CI, 7.1-10.7 months), and the median OS was 19.0 months. Exploratory biomarker analysis revealed that lactic dehydrogenase (LDH) was a potential marker for OS, and patients with high LDH levels had shorter mOS (13.0 months, 95% CI:7.5-18.5 months). Treatment-related adverse events (AEs) occurred in 21 patients (95.5%), most of which were grade 1 or 2. No treatment-related deaths occurred in this study. The results of this study suggested that sintilimab combined with Nab-PTX and platinum in patients with metastatic ESCC had a significantly high ORR and encouraging mPFS and mOS. LDH was a potential marker for OS, and the safety profile was manageable.
BibTeX
@inproceedings{zhao2023efficacy,
  author = {Zheng Zhao and Ming-Mei Yin and Weifeng Zhao and Chao‐Jie Wang},
  title = {{The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma}},
  booktitle = {Medicine},
  year = {2023},
  doi = {10.1097/md.0000000000034794},
}
Figure